Compare Adaptive Biotechnologies Corp (ADPT) vs CF Industries Holdings, Inc. (CF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs CF Industries Holdings, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while CF Industries Holdings, Inc. trades at $116.35 (market cap $17.66B). The key difference: CF Industries Holdings, Inc. is far larger — about 5.3× Adaptive Biotechnologies Corp's market cap, and CF Industries Holdings, Inc. pays a 1.74% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CF | |
|---|---|---|
Market Cap | $3.33B | $17.66B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $137.55 |
52-Week Low | $10.24 | $76.08 |
Enterprise Value | $3.19B | $19.24B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CF Industries stock trades at $114.92, up 3.96% today, with a bullish technical signal and strong fundamental metrics including a P/E of 10.2 and net income margin of 23.73%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $5.71. Recent news highlights robust nitrogen demand and cash flow strength, though rising natural gas costs pose margin pressure.
The outlook remains positive given favorable analyst sentiment, with a consensus price target of $126.67 and 51% buy ratings. Key risks include input cost volatility and geopolitical factors affecting fertilizer markets, but the company's low-cost position and solid balance sheet support continued shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →
